Opiant Pharmaceuticals with ticker code (OPNT) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 44 and 38 and has a mean target at 41.33. Given that the stocks previous close was at 8.04 this now indicates there is a potential upside of 414.1%. There is a 50 day moving average of 8.08 and the 200 day MA is 8.45. The company has a market cap of $34m. Find out more information at: http://www.opiant.com
The potential market cap would be $176m based on the market concensus.
Opiant Pharmaceuticals, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals in January 2016. Opiant Pharmaceuticals was founded in 2005 and is headquartered in Santa Monica, California.
